208 related articles for article (PubMed ID: 33389670)
1. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.
Tosaki T; Okabe M; Suzuki T; Shimizu A; Koike K; Tsuboi N; Kawamura T; Ohashi R; Yano S; Yokoo T
CEN Case Rep; 2021 May; 10(2):265-272. PubMed ID: 33389670
[TBL] [Abstract][Full Text] [Related]
2. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.
Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y
BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741
[TBL] [Abstract][Full Text] [Related]
4. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
[TBL] [Abstract][Full Text] [Related]
5. Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.
Kojima D; Yamaguchi S; Hashiguchi A; Hayashi K; Uchiyama K; Yoshimoto N; Adachi K; Nakayama T; Nishioka K; Tajima T; Morimoto K; Yoshino J; Yoshida T; Monkawa T; Kanda T; Itoh H
Front Med (Lausanne); 2022; 9():1037032. PubMed ID: 36698794
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
Tabata S; Higuchi T; Tatsukawa S; Narimatsu K; Takeo H; Matsukuma S; Ito T
Intern Med; 2019 Nov; 58(22):3313-3318. PubMed ID: 31292389
[TBL] [Abstract][Full Text] [Related]
7. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
Front Immunol; 2019; 10():1489. PubMed ID: 31316523
[No Abstract] [Full Text] [Related]
8. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
Sugawara E; Sato T; Amasaki Y; Katsumata K
Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.
Fujiwara S; Mochinaga H; Nakata H; Ohshima K; Matsumoto M; Uchiba M; Mikami Y; Hata H; Okuno Y; Mitsuya H; Nosaka K
Int J Hematol; 2016 Jun; 103(6):718-23. PubMed ID: 26980221
[TBL] [Abstract][Full Text] [Related]
10. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
Zhou Q; Zhang Y; Zhou G; Zhu J
BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
[TBL] [Abstract][Full Text] [Related]
11. TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.
Tu KH; Fan PY; Chen TD; Chuang WY; Wu CY; Ku CL; Tian YC; Yang CW; Fang JT; Yang HY
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208103
[TBL] [Abstract][Full Text] [Related]
12. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K
BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T
Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172
[TBL] [Abstract][Full Text] [Related]
14. [Thrombotic microangiopathy developing subsequent to tocilizumab therapy in a patient with TAFRO syndrome].
Ito S; Tsutsumi Y; Kikuchi R; Matsuoka S; Shimoyama N
Rinsho Ketsueki; 2018; 59(11):2432-2437. PubMed ID: 30531139
[TBL] [Abstract][Full Text] [Related]
15. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
[TBL] [Abstract][Full Text] [Related]
16. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab.
Aita T; Hamaguchi S; Shimotani Y; Nakamoto Y
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148595
[TBL] [Abstract][Full Text] [Related]
19. A Case of the nephrotic syndrome in bone marrow transplantation recipient, histologically showing overlapped glomerular lesions of thrombotic microangiopathy and membranous nephropathy.
Masuzawa N; Nishimura A; Kitani T; Tamagaki K; Sugitani M; Nagoshi H; Kuroda J; Konishi E
Pathol Int; 2017 Dec; 67(12):620-625. PubMed ID: 28940837
[TBL] [Abstract][Full Text] [Related]
20. Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease.
Togitani K; Ogasawara F; Arakawa Y; Sugimura N; Miyazaki R; Kojima K
Intern Med; 2023 Feb; 62(3):449-452. PubMed ID: 35732449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
